Appearing as a significant development in the battle against obesity, this medication is attracting considerable interest . This treatment combines the action of two recognized GLP-1 binding agonists, liraglutide, plus an additional glucose-dependent incretin component. Initial study results have indicated substantial fat loss in people with a hig